Am I a good candidate for an implanted venous access device?

 

Q: Am I a good candidate for an implanted venous access device? 

A: A venous access device, or VAD, is a catheter or port that is surgically placed in your body to give access to a major vein. These devices are often used with patients who are receiving long-term chemotherapy, chemotherapy that is infused by a portable pump over days, frequent blood tests, transfusions, or other treatment-related care. Some patients on chemotherapy receive VAD implants, others don't.

Whether you will have a VAD depends upon your treatment plan, the physical condition of your veins, and other factors your doctor will consider. While you're in treatment, your VAD will need to be flushed after each session to keep it from becoming clogged. After treatment ends, you'll need to have it flushed every 4 to 6 weeks.
--Bernice Crook, RN, OCN

Cancer patients have greater risk of blood clots, but can watch for danger signals.

Latest Cancer News
Urinary Prostate Cancer Test, PCA3, Predictive of Biopsy Outcomes

March 9, 2010 — Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that the urinary PCA3 test can predict biopsy outcome in men taking dutasteride. The details of two studies were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium held in San Francisco, March 5-7.

HPV Vaccine Provides Little Benefit for Older Women

March 9, 2010 — Researchers from Costa Rica have reported that women over the age of 40 are not likely to benefit from vaccination to prevent human papillomavirus (HPV). The details of this study were published in the March 3, 2010 issue of the Journal of the National Cancer Institute.

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Arimidex

March 9, 2010 — Among postmenopausal women with early, hormone receptor-positive breast cancer treated with either tamoxifen (Nolvadex®) or Arimidex® (anastrozole), the Oncotype DX test predicts the risk of distant cancer recurrence in both node-negative and node-positive patients. These results were published in the Journal of Clinical Oncology.

Select news items provided by Reuters Health